批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2019/05/10 |
SUPPL-38(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/04/27 |
SUPPL-37(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/09/25 |
SUPPL-36(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/07/20 |
SUPPL-35(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2015/09/30 |
SUPPL-34(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/03/23 |
SUPPL-32(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2015/02/19 |
SUPPL-33(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/11/18 |
SUPPL-30(补充) |
Approval |
Labeling |
901 REQUIRED
|
|
|
2006/10/25 |
SUPPL-27(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2006/06/13 |
SUPPL-25(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2004/11/22 |
SUPPL-21(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2004/09/29 |
SUPPL-22(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2003/11/13 |
SUPPL-20(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/12/24 |
SUPPL-19(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
2002/10/08 |
SUPPL-15(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/09/13 |
SUPPL-18(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
2002/06/24 |
SUPPL-16(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2002/03/01 |
SUPPL-17(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2001/06/19 |
SUPPL-14(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2001/03/06 |
SUPPL-13(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2001/01/05 |
SUPPL-12(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1999/10/18 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
1999/10/08 |
SUPPL-11(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
1999/03/23 |
SUPPL-7(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
1999/03/08 |
SUPPL-9(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1999/03/08 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1998/02/03 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
1997/12/15 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1997/12/15 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1997/11/13 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
1997/04/11 |
SUPPL-2(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
1996/07/31 |
SUPPL-1(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1995/11/17 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:LAMIVUDINE 剂型/给药途径:SOLUTION;ORAL 规格:10MG/ML 治疗等效代码:AA
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020596 |
001 |
NDA |
EPIVIR |
LAMIVUDINE |
SOLUTION;ORAL |
10MG/ML |
Prescription |
Yes |
Yes |
AA |
1995/11/17
|
VIIV HLTHCARE |
203564 |
001 |
ANDA |
LAMIVUDINE |
LAMIVUDINE |
SOLUTION;ORAL |
10MG/ML |
Prescription |
No |
No |
AA |
2014/10/31
|
CHARTWELL MOLECULAR |
077695 |
001 |
ANDA |
LAMIVUDINE |
LAMIVUDINE |
SOLUTION;ORAL |
10MG/ML |
Prescription |
No |
No |
AA |
2016/11/21
|
AUROBINDO PHARMA |
091475 |
001 |
ANDA |
LAMIVUDINE |
LAMIVUDINE |
SOLUTION;ORAL |
10MG/ML |
Prescription |
No |
No |
AA |
2023/10/06
|
HETERO LABS LTD III |